UroGen Pharma (URGN) Share-based Compensation (2017 - 2026)
UroGen Pharma's (URGN) quarterly Share-based Compensation came in at $39.1 million in Q1 2026, up 1174.03% YoY from $3.1 million in Q1 2025, and up 1149.2% on a QoQ basis from $3.1 million in Q4 2025.
UroGen Pharma (URGN) Share-based Compensation (2017 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 10 years of Share-based Compensation data on file, last reported at $39.1 million in Q1 2026.
- Quarterly Share-based Compensation rose 1174.03% year-over-year to $39.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39.1 million (up 191.33% YoY) and the FY2025 annual result came in at $12.0 million, down 8.77% from the prior year.
- Share-based Compensation advanced to $39.1 million in Q1 2026, from $3.1 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $39.1 million in Q1 2026 to a low of $2.2 million in Q2 2023.
- A 5-year average of $5.9 million and a median of $2.9 million in 2022 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation tumbled 55.8% — and 2026, when it jumped 1174.03%.
- Tracing URGN's Share-based Compensation over 5 years: stood at $2.4 million in 2022, then increased by 10.3% to $2.6 million in 2023, then rose by 26.45% to $3.3 million in 2024, then slipped by 5.24% to $3.1 million in 2025, then jumped by 1149.2% to $39.1 million in 2026.
- The last three Share-based Compensation figures came in at $39.1 million (Q1 2026), $3.1 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn | 39.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39.00 Mn |
| Jun 30, 2026 | 39.00 Mn |
| Mar 31, 2026 | 39.10 Mn |
| Mar 31, 2026 | 39.10 Mn |
| Dec 31, 2025 | 3.13 Mn |
| Dec 31, 2025 | 3.13 Mn |
| Sep 30, 2025 | 3.03 Mn |
| Sep 30, 2025 | 3.03 Mn |
| Jun 30, 2025 | 18.30 Mn |
| Jun 30, 2025 | 18.30 Mn |
| Mar 31, 2025 | 3.07 Mn |
| Mar 31, 2025 | 3.07 Mn |
| Dec 31, 2024 | 3.30 Mn |
| Dec 31, 2024 | 3.30 Mn |
| Sep 30, 2024 | 3.49 Mn |
| Sep 30, 2024 | 3.49 Mn |
| Jun 30, 2024 | 3.56 Mn |
| Jun 30, 2024 | 3.56 Mn |
| Mar 31, 2024 | 2.76 Mn |
| Mar 31, 2024 | 2.76 Mn |